布鲁顿酪氨酸激酶抑制剂治疗复发/难治型套细胞淋巴瘤安全性和有效性的meta分析

Efficacy and safety of Bruton's tyrosine kinase inhibitors in relapsed/refractory mantle cell lymphoma patients:a meta-analysis

目的系统评价布鲁顿酪氨酸激酶(BTK)抑制剂(阿卡替尼、泽布替尼、伊布替尼和奥布替尼)治疗复发/难治型套细胞淋巴瘤(R/R MCL)的有效性和安全性。方法参考Cochrane手册,检索Embase、Cochrane library、Medline、中国知网、万方数据知识服务平台,检索时间从2010年1月至2023年2月,筛选符合纳入和排除标准的文献,对纳入文献质量进行评价,采用RevMan 5.4和R4.0.5软件进行meta分析。结果共纳入9篇文献。meta分析结果显示,R/R MCL完全缓解率(CRR)以伊布替尼联合利妥昔单抗组最高,且联合治疗组在腹泻、恶心和疲劳方面有更高的发生率。结论BTK抑制剂对R/R MCL具有显著的抗肿瘤活性,且安全性良好。

Objective To systematically evaluate the efficacy and safety of Bruton's tyrosine kinase(BTK)inhibitors(acalabrutinib,zanubrutinib,and ibrutinib and orelabrutinib)in relapsed/refractory mantle cell lymphoma(R/R MCL)and provide a reference for clinical therapy.Methods According to the Cochrane manual,five databases including Embase,Cochrane Library,CNKI,Wanfang,and Medline database were searched from January 2010 to February 2023.The literatures were screened according to the inclusion and exclusion criteria,basic data were extracted,and the quality of included literature was evaluated.RevMan5.4 and R 4.0.5 software were used for meta-analysis.Results Nine studies were included in the meta-analysis.Meta-analysis showed that the CRR comparison was highest in the ibrutinib combined with the rituximab group.According to safety outcomes,the combination treatment group was associated with a higher incidence of diarrhea,nausea,and fatigue.Conclusion BTK inhibitors have significant anti-tumor activity and good safety in R/R MCL patients.